DoubleTwist has withdrawn its initial public offering and laid off “around 20 people” in a move to streamline its operations, said spokeswoman Nicole Litchfield. The layoffs represent approximately 10 percent of DoubleTwist’s staff.

“In light of current market conditions, we believe it is in the best interest of our shareholders to withdraw our registration statement for a public offering at this time,” Litchfield said.

DoubleTwist anticipated offering 5.75 million common shares priced at $13-$15, for a proposed offering price of $86.3 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.